









Mercados
/
Ações
/
nasdaq-gild
/

Gilead Sciences Inc

GILD

108.220USD

-0.580-0.53%

Fechamento 07/18, 16:00（ET）Cotações atrasadas em 15 min

134.73BValor de mercado

22.59P/L TTM



Gilead Sciences Inc

108.220

-0.580-0.53%

Visão Geral Empresa Serviços Financeiros

Serviços Financeiros

Mais detalhes de Gilead Sciences Inc Empresa

Gilead Sciences, Inc. is a biopharmaceutical company. The Company is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, COVID-19, cancer and inflammation. It is focused on discovering, developing and delivering medicines to address unmet medical needs in virology, oncology and other therapeutic areas. Its portfolio of marketed products includes Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, and Letairis. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Anitocabtagene autoleucel, Sacituzumab govitecan-hziy, and Domvanalimab and zimberelimab. Biktarvy is an oral formulation dosed once a day for the treatment of HIV-1 infection in certain patients. It operates in more than 35 countries worldwide.

Informações da empresa

Código da empresaGILD

Nome da EmpresaGilead Sciences Inc

Data de listagemJan 22, 1992

Fundado em1987

CEOMr. Daniel P. O'Day

Número de funcionários17600

Tipo de títulosOrdinary Share

Fim do ano fiscalJan 22

Endereço333 Lakeside Dr

CidadeFOSTER CITY

Bolsa de valoresNASDAQ Global Select Consolidated

PaísUnited States of America

Código postal94404-1147

Telefone16505743000

Sitehttps://www.gilead.com/

Código da empresaGILD

Data de listagemJan 22, 1992

Fundado em1987

Executivos da empresa

Nome

Nome/Posição

Posição

Ações detidas

Variação

Ms. Johanna Mercier

Chief Commercial Officer

89.94K

-3.23%

Dr. Jacqueline K. Barton, Ph.D.

Independent Director

26.06K

+6.18%

Ms. Deborah H. (Deb) Telman

Executive Vice President - Corporate Affairs, General Counsel

20.78K

+4.44%

Mr. Anthony (Tony) Welters, J.D.

Lead Independent Director

11.75K

+14.82%

Ms. Kelly A. Kramer

Independent Director

1.34K

Dr. Dietmar P. Berger, M.D., Ph.D.

Chief Medical Officer

Mr. Andrew D. (Andy) Dickinson

Chief Financial Officer

Mr. Harish Manwani

Independent Director

Dr. Ted W. Love, M.D.

Independent Director

Mr. Javier J. Rodriguez

Independent Director

Ver Mais

Nome

Nome/Posição

Posição

Ações detidas

Variação

Ms. Johanna Mercier

Chief Commercial Officer

89.94K

-3.23%

Dr. Jacqueline K. Barton, Ph.D.

Independent Director

26.06K

+6.18%

Ms. Deborah H. (Deb) Telman

Executive Vice President - Corporate Affairs, General Counsel

20.78K

+4.44%

Mr. Anthony (Tony) Welters, J.D.

Lead Independent Director

11.75K

+14.82%

Ms. Kelly A. Kramer

Independent Director

1.34K

Dr. Dietmar P. Berger, M.D., Ph.D.

Chief Medical Officer

Detalhamento da receita

Moeda: USDAtualizado em: dom, 6 de jul

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

FY2017

FY2016

FY2015

Por EmpresaUSD

Nome

Receita

Proporção

Biktarvy

3.15B

47.25%

Descovy

586.00M

8.79%

Yescarta

386.00M

5.79%

Genvoya

364.00M

5.46%

Sofosbuvir/Velpatasvir

345.00M

5.17%

Other

1.84B

27.54%

Por RegiãoUSD

Nome

Receita

Proporção

United States

4.47B

67.02%

Europe

1.06B

15.94%

Other Locations

829.00M

12.43%

Por Empresa

Por Região

Por EmpresaUSD

Nome

Receita

Proporção

Biktarvy

3.15B

47.25%

Descovy

586.00M

8.79%

Yescarta

386.00M

5.79%

Genvoya

364.00M

5.46%

Sofosbuvir/Velpatasvir

345.00M

5.17%

Other

1.84B

27.54%

Distribuição de ações

Atualizado em: qui, 15 de mai

Investidores

Tipos de investidores

Investidores

Proporção

The Vanguard Group, Inc.

9.40%

BlackRock Institutional Trust Company, N.A.

5.68%

State Street Global Advisors (US)

4.79%

Capital Research Global Investors

4.39%

Capital World Investors

4.30%

Other

71.44%

Investidores

Proporção

The Vanguard Group, Inc.

9.40%

BlackRock Institutional Trust Company, N.A.

5.68%

State Street Global Advisors (US)

4.79%

Capital Research Global Investors

4.39%

Capital World Investors

4.30%

Other

71.44%

Tipos de investidores

Investidores

Proporção

Investment Advisor

43.46%

Investment Advisor/Hedge Fund

34.73%

Research Firm

2.92%

Pension Fund

2.91%

Hedge Fund

2.04%

Bank and Trust

1.84%

Sovereign Wealth Fund

1.72%

Insurance Company

0.13%

Individual Investor

0.08%

Other

10.16%

Participação acionária institucional

Atualizado em: ter, 1 de jul

Período do relatório

N.º de instituições

Ações detidas

Proporção

Variação

2025Q2

3339

1.12B

89.81%

-9.85M

2025Q1

3442

1.12B

90.14%

-10.49M

2024Q4

3313

1.12B

90.13%

+4.63M

2024Q3

3207

1.10B

88.48%

-11.56M

2024Q2

3188

1.10B

88.24%

-14.37M

2024Q1

3196

1.10B

88.13%

-22.04M

2023Q4

3252

1.11B

88.75%

-8.79M

2023Q3

3190

1.10B

88.14%

-23.58M

2023Q2

3196

1.10B

88.02%

-11.22M

2023Q1

3195

1.09B

87.26%

-11.17M

Ver Mais

Atividade dos acionistas

Nome

Ações detidas

Proporção

Variação

Var. %

Data

The Vanguard Group, Inc.

116.91M

9.4%

+1.94M

+1.69%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

70.66M

5.68%

-3.80M

-5.11%

Mar 31, 2025

State Street Global Advisors (US)

59.52M

4.79%

-858.08K

-1.42%

Mar 31, 2025

Capital Research Global Investors

54.61M

4.39%

-3.34M

-5.76%

Mar 31, 2025

Capital World Investors

53.55M

4.3%

-18.16M

-25.32%

Mar 31, 2025

Fidelity Management & Research Company LLC

51.21M

4.12%

+16.57M

+47.83%

Mar 31, 2025

Dodge & Cox

32.69M

2.63%

-252.93K

-0.77%

Mar 31, 2025

Geode Capital Management, L.L.C.

28.48M

2.29%

+190.23K

+0.67%

Mar 31, 2025

Wellington Management Company, LLP

27.36M

2.2%

-8.30M

-23.28%

Mar 31, 2025

Invesco Capital Management (QQQ Trust)

25.70M

2.07%

-130.67K

-0.51%

Jun 30, 2025

Ver Mais

ETFs Relacionados

Atualizado em: dom, 6 de jul

Nome

Proporção

VanEck Biotech ETF

13.56%

Invesco Nasdaq Biotechnology ETF

8.68%

ProShares Ultra Nasdaq Biotechnology

7.94%

iShares Biotechnology ETF

7.81%

Coastal Compass 100 ETF

5.83%

Invesco Pharmaceuticals ETF

5.41%

Invesco Biotechnology & Genome ETF

5.25%

ProShares Nasdaq-100 Dorsey Wright Momentum ETF

4.41%

USCF Dividend Income Fund

4.27%

First Trust NASDAQ Pharmaceuticals ETF

3.9%

Ver Mais

VanEck Biotech ETF

Proporção13.56%

Invesco Nasdaq Biotechnology ETF

Proporção8.68%

ProShares Ultra Nasdaq Biotechnology

Proporção7.94%

iShares Biotechnology ETF

Proporção7.81%

Coastal Compass 100 ETF

Proporção5.83%

Invesco Pharmaceuticals ETF

Proporção5.41%

Invesco Biotechnology & Genome ETF

Proporção5.25%

ProShares Nasdaq-100 Dorsey Wright Momentum ETF

Proporção4.41%

USCF Dividend Income Fund

Proporção4.27%

First Trust NASDAQ Pharmaceuticals ETF

Proporção3.9%

Dividendo

Um total de 18.49B USD foi distribuído em dividendos nos últimos 5 anos.

Data

Dividendo

Data de registro

Data de pagamento

Data ex-dividendo

Feb 11, 2025

GILD.NB Interim Cash Dividend of gross USD 0.79 paid on Mar 28, 2025 going ex on Mar 14, 2025

Mar 14, 2025

Mar 28, 2025

Mar 14, 2025

Nov 12, 2024

GILD.NB Final Cash Dividend of gross USD 0.77 paid on Dec 30, 2024 going ex on Dec 13, 2024

Dec 13, 2024

Dec 30, 2024

Dec 13, 2024

Aug 13, 2024

GILD.NB Interim Cash Dividend of gross USD 0.77 paid on Sep 27, 2024 going ex on Sep 13, 2024

Sep 13, 2024

Sep 27, 2024

Sep 13, 2024

Apr 26, 2024

GILD.NB Interim Cash Dividend of gross USD 0.77 paid on Jun 27, 2024 going ex on Jun 14, 2024

Jun 14, 2024

Jun 27, 2024

Jun 14, 2024

Feb 06, 2024

GILD.NB Interim Cash Dividend of gross USD 0.77 paid on Mar 28, 2024 going ex on Mar 14, 2024

Mar 15, 2024

Mar 28, 2024

Mar 14, 2024

Nov 08, 2023

GILD.NB Final Cash Dividend of gross USD 0.75 paid on Dec 28, 2023 going ex on Dec 14, 2023

Dec 15, 2023

Dec 28, 2023

Dec 14, 2023

Aug 07, 2023

GILD.NB Interim Cash Dividend of gross USD 0.75 paid on Sep 28, 2023 going ex on Sep 14, 2023

Sep 15, 2023

Sep 28, 2023

Sep 14, 2023

Apr 28, 2023

GILD.NB Interim Cash Dividend of gross USD 0.75 paid on Jun 29, 2023 going ex on Jun 14, 2023

Jun 15, 2023

Jun 29, 2023

Jun 14, 2023

Feb 02, 2023

GILD.NB Interim Cash Dividend of gross USD 0.75 paid on Mar 30, 2023 going ex on Mar 14, 2023

Mar 15, 2023

Mar 30, 2023

Mar 14, 2023

Oct 27, 2022

GILD.NB Final Cash Dividend of gross USD 0.73 paid on Dec 29, 2022 going ex on Dec 14, 2022

Dec 15, 2022

Dec 29, 2022

Dec 14, 2022

Ver Mais

Desdobramento de ações

Data

Tipo

Proporção

Sem dados

Data

Tipo

Proporção

Sem dados

KeyAI

